La vendita allo scoperto per Codexis dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Codexis. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Codexis (NASDAQ:CDXS) Azioni, Report sulle vendite allo scoperto

Codexis

Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.

Codexis Inc

Benchmark analyst Robert Wasserman reiterates Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Hold.

News

Reiteration

Analyst Ratings

CDXS

Benchmark Reiterates Hold on Codexis

WIIM

Codexis shares are trading higher after the company reported better-than-expected Q3 revenue results.

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) affirms FY2024 sales outlook from $56.00 million-64.00 million to $56.00 million-64.00 million.

Guidance

Codexis Affirms FY2024 Product revenues $38M-$42M, R&D revenues $18M-$22M.

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.23) by 26.09 percent. The company reported quarterly sales of $12.833 million which beat the analyst consensus estimate of $11.482 million by 11.77 percent. This is a 38.33 percent increase over sales of $9.277 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Codexis Q3 2024 GAAP EPS $(0.29) Misses $(0.23) Estimate, Sales $12.833M Beat $11.482M Estimate

Management

Codexis Says Sriram Ryali Ceased To Serve As CFO And Principal Financial And Accounting Officer Effective As Of September 30, 2024

These funds are in addition to the&nbsp;$73.2 million&nbsp;in cash, cash equivalents and investments on hand as of June 30, 2024.&nbsp;In addition to the financing, the Company strengthened its management team through the appointments of Alison Moore&nbsp;to the newly created role of Chief Technology Officer and Georgia Erbez as Chief Financial Officer.

Codexis Reports Increase In Its Cash Reserves Through Capital Raises Totaling $31M Via Existing ATM Facility, Bringing Cash Runway Into 2027; Georgia Erbez Named As CFO

Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading enzyme engineering company, today announced it has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme LLC, part of Maravai LifeSciences, for multiple enzymes in Codexis' life science enzyme portfolio. The agreement includes licenses for the HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes that were in development directed towards genomics and diagnostics applications prior to the Company's strategic shift announced in July 2023. Under the terms of the agreement, Codexis is eligible to receive sales-based royalties. &nbsp;
"As our manufacturing partner for the past three years—and with an existing genomics enzyme portfolio and sales force —Alphazyme is the natural choice to extend our commercial reach into this segment. We anticipate a smooth transition for our customers as there is no change in manufacturing supply and many of our customers are already familiar with the Alphazyme team," said Kevin Norrett, MBA, Chief Operating Officer at Codexis. "This transaction enables Codexis to maintain its focus on maximizing our near-term commercial opportunities and strategic priorities. This includes the growth of our Pharmaceutical Manufacturing business, increasing commercial adoption of the dsRNA ligase, and the build-out of our ECO Synthesis&#x2122; Innovation Lab to support manufacturing process development for our customers' preclinical siRNA assets. We remain on track to achieve key milestones for the ECO Synthesis&#x2122; platform this fiscal year, while delivering double-digit product revenue growth and maintaining a path to positive cash flow around the end of 2026."
Alphazyme is a premier partner for industrial-scale molecular biology enzymes. Alphazyme enthusiastically collaborates with manufacturers of nucleic acid synthesis and detection platforms to produce affordable, custom enzyme formulations of the highest quality that meet the specifications of the rapidly expanding markets for custom DNA and RNA molecules, genomic medicines and genetic testing.&nbsp;"The Codexis and Alphazyme relationship has been strong for many years. We are excited to take on Codexis' portfolio of high-performing life science and diagnostic enzymes and be a part of their continued success," said Chad Decker, Vice President and General Manager of Alphazyme. This new collaboration will leverage the experience and industry knowledge of the Alphazyme team to enhance the commercialization of Codexis' portfolio of life science and diagnostic enzymes.
This license agreement marks another transaction in which Codexis is executing on its strategy to divest the Company's non-core assets following its strategic shift to focus on the growth of its Pharmaceutical Manufacturing business and Enzyme Catalyzed Oligonucleotide (ECO) Synthesis&#x2122; manufacturing platform.

MRVI

Codexis Licenses Key Enzymes to Alphazyme, Sharpening Focus on Pharmaceutical Growth

Cantor Fitzgerald analyst Kristen Kluska reiterates Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Overweight and maintains $11 price target.

Price Target

Cantor Fitzgerald Reiterates Overweight on Codexis, Maintains $11 Price Target

Benchmark analyst Robert Wasserman downgrades Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) from Buy to Hold.

Downgrades

Benchmark Downgrades Codexis to Hold

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.25) by 28 percent. The company reported quarterly sales of $7.979 million which beat the analyst consensus estimate of $7.825 million by 1.97 percent. This is a 62.58 percent decrease over sales of $21.323 million the same period last year.

Codexis Q2 2024 GAAP EPS $(0.32) Misses $(0.25) Estimate, Sales $7.979M Beat $7.825M Estimate

Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company's investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty. &nbsp;

Contracts

Codexis Finalizes Purchase Agreement With Crosswalk Therapeutics For Gene Therapy Assets; Codexis Is Eligible To Receive Future Development And Commercial Milestone Payments In Addition To A Low-To-Mid Single-Digit Percentage Net Sales-Based Royalty

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Overweight rating and announces Price Target of $11.

Initiation

Cantor Fitzgerald Initiates Coverage On Codexis with Overweight Rating, Announces Price Target of $11

Health Care

General

Codexis Successfully Synthesizes An Oligonucleotide Via An Enzymatic Route To Support RNA-Based Therapeutics Manufacturing

Benchmark analyst Robert Wasserman reiterates Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Buy and maintains $9 price target.

Benchmark Reiterates Buy on Codexis, Maintains $9 Price Target

Codexis shares are trading higher after the company reported better-than-expected Q1 financial results.

Codexis Reiterates 2024 Product Revenue Guidance $38M-$42M Excluding Revenue Related To PAXLOVID

Codexis Files $200M Mixed Securities Shelf

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 52.94 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $17.073 million which beat the analyst consensus estimate of $13.660 million by 24.98 percent. This is a 31.51 percent increase over sales of $12.982 million the same period last year.

Codexis Q1 2024 GAAP EPS $(0.16) Beats $(0.18) Estimate, Sales $17.073M Beat $13.660M Estimate

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Codexis (CDXS – Research Report). The company's shares closed ...

Codexis (CDXS) Receives a Buy from Craig-Hallum

Artiva Biotherapeutics (ARTV) announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore bring...

Artiva Biotherapeutics appoints Alison Moore, Ph.D., to Its Board of Directors

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Next Science Ltd (NXSCF – Research Report) and Codex...

Analysts Offer Insights on Healthcare Companies: Next Science Ltd (OtherNXSCF) and Codexis (CDXS)

In a report released today, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Codexis (CDXS – Research Report). The company's shares closed ...

Craig-Hallum Sticks to Its Buy Rating for Codexis (CDXS)

Codexis GAAP EPS of -$0.29 misses by $0.05, revenue of $12.93M beats by $1.45M

Reports Q3 revenue $12.83M, consensus $11.48M. "Codexis (CDXS) had a strong third quarter, in which we surpassed product revenue goals, welcomed tw...

Codexis reports Q3 EPS (29c), consensus (24c)

Codexis, Inc. 2024 Q3 - Results - Earnings Call Presentation

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Codexis ( ($CDXS) ) has released its Q3 earnings. Here is a breakdown of the information Codexis presented to its investors. Codexis, Inc., a promi...

Codexis Reports Strong Q3 Revenue Growth

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Codexis (CDXS – Research Report) today and set a price target of $5.00. The company...

Comments

Codexis

Vendite allo scoperto

Codexis (NASDAQ:CDXS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO